Loading
SI
Synthorx, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by ORBIMED ADVISORS LLC, was filed 13 Dec 2018.
Synthorx, Inc.: what insiders have been doing
Every trade that managers of Synthorx, Inc. disclose to SEC (Form 4) is tracked on this page. Nothing new has been filed by managers of Synthorx, Inc. in twelve months, the latest record being from 24 January 2020.
Our records for Synthorx, Inc. go back to 2018, with 7 purchases and no sales on the open market in total.
Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
52
Thresholds
n/a
Buy Volume
€130M
7 ops. · all time
Sell Volume
n/a
n/a
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2019FY ended September 2019 · cache
Last declaration on 24 January 2020
Declarations52 total
80,706 shares0Common StockSEC:0001209191-20-004929:0
9,724,598 shares@ US$68.00100.0% of flowCommon StockSEC:0001104659-20-006828:0
63,989 shares@ US$68.0054.0% of flowCommon StockSEC:0001209191-20-004925:0
5,316,355 shares@ US$68.0096.1% of flowCommon StockSEC:0001209191-20-004930:0
220,595 shares@ US$68.0045.5% of flowCommon StockSEC:0001209191-20-004929:1
25,000 shares@ US$68.005.2% of flowCommon StockSEC:0001209191-20-004929:2
9,724,598 shares@ US$68.0093.1% of flowCommon StockSEC:0001209191-20-004921:0
43,688 shares@ US$68.002.4% of flowCommon StockSEC:0001209191-20-004927:0
1,682,086 shares@ US$68.0092.8% of flowCommon StockSEC:0001209191-20-004927:1
62,412 shares@ US$68.00100.0% of flowCommon StockSEC:0001209191-20-004928:0
150,000 shares@ US$68.006.3% of flowCommon StockSEC:0001209191-20-004924:0
448,567 shares@ US$68.0019.0% of flowCommon StockSEC:0001209191-20-004924:1
1,682,086 shares@ US$68.0071.1% of flowCommon StockSEC:0001209191-20-004924:2
316,164 shares@ US$68.0084.4% of flowCommon StockSEC:0001209191-20-004923:0
4,598,796 sharesCommon StockSEC:0001209191-20-003667:0
4,598,796 sharesCommon StockSEC:0001209191-20-003673:0
448,567 sharesCommon StockSEC:0001209191-20-003673:1
98,462 shares@ US$0.930.3% of flowCommon StockSEC:0001209191-20-000319:0
12,912 shares@ US$0.930.0% of flowCommon StockSEC:0001209191-20-000319:1
147,264 shares@ US$0.630.3% of flowCommon StockSEC:0001209191-20-000319:2
120,815 shares@ US$11.004.0% of flowCommon StockSEC:0001209191-20-000319:3
210,010 shares@ US$70.6344.7% of flowCommon StockSEC:0001209191-20-000319:4
98,000 shares@ US$0.630.8% of flowCommon StockSEC:0001209191-20-000325:0
52,011 shares@ US$70.6345.2% of flowCommon StockSEC:0001209191-20-000325:1
75,000 shares@ US$11.003.2% of flowCommon StockSEC:0001209191-20-000329:0
25 of 52 declarations
About Synthorx, Inc.
Synthorx, Inc. is a biopharmaceutical company focused on developing therapies based on synthetic nucleic acids. It aims to enhance disease treatment using its unique technology.
